12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-04-18), Phathom Pharmaceuticals's 12-1 Month Momentum % is -18.52%.
The industry rank for Phathom Pharmaceuticals's 12-1 Month Momentum % or its related term are showing as below:
PHAT's 12-1 Month Momentum % is ranked better than 57.59% of 1483
companies
in the Biotechnology industry
Industry Median: -25.1
vs PHAT: -18.52
Competitive Comparison
For the Biotechnology subindustry, Phathom Pharmaceuticals's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Phathom Pharmaceuticals 12-1 Month Momentum % Distribution
For the Biotechnology industry and Healthcare sector, Phathom Pharmaceuticals's 12-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Phathom Pharmaceuticals's 12-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Phathom Pharmaceuticals 12-1 Month Momentum % Related Terms
Thank you for viewing the detailed overview of Phathom Pharmaceuticals's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.
Phathom Pharmaceuticals (Phathom Pharmaceuticals) Business Description
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PHAT has been successfully added to your